Inflammation-related cytokines in oral lichen planus: An overview

Journal of Oral Pathology and Medicine

Volumn 44, Issue 1, 2015, Pages 1-14

  Lu, Rui ^a   Zhang, Jing ^a   Sun, Wei ^a   Du, Gefei ^a   Zhou, Gang ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

Cytokine; Oral lichen planus; Overview

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; AUTACOID; INTERLEUKIN DERIVATIVE;

ADAPTIVE IMMUNITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; INNATE IMMUNITY; LICHEN PLANUS; MOUTH MUCOSA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN FUNCTION; REVIEW; SALIVA; SERUM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY;

CYTOKINES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; INTERFERON-GAMMA; INTERLEUKINS; LICHEN PLANUS, ORAL; POLYMORPHISM, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920277564     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12142     Document Type: Review

References (147)

1. Eisen D, Carrozzo M, Bagan Sebastian JV, Thongprasom K. Number V Oral lichen planus: clinical features and management. Oral Dis 2005; 11: 338-49.
2. Lodi G, Scully C, Carrozzo M, Griffiths M, Sugerman PB, Thongprasom K. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2005; 100: 40-51.
3. Sugerman PB, Savage NW, Walsh LJ, et al. The pathogenesis of oral lichen planus. Crit Rev Oral Biol Med 2002; 13: 350-65.
4. Payeras MR, Cherubini K, Figueiredo MA, Salum FG. Oral lichen planus: focus on etiopathogenesis. Arch Oral Biol 2013; 58: 1057-69.
5. Rhodus NL, Cheng B, Ondrey F. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus. Mediators Inflamm 2007; 2007: 19854.
6. Yamamoto T, Osaki T. Characteristic cytokines generated by keratinocytes and mononuclear infiltrates in oral lichen planus. J Invest Dermatol 1995; 104: 784-8.
7. Iijima W, Ohtani H, Nakayama T, et al. Infiltrating CD8+ T cells in oral lichen planus predominantly express CCR5 and CXCR3 and carry respective chemokine ligands RANTES/CCL5 and IP-10/CXCL10 in their cytolytic granules: a potential self-recruiting mechanism. Am J Pathol 2003; 163: 261-8.
8. Zhou G, Xia K, Du GF, et al. Activation of nuclear factor-kappa B correlates with tumor necrosis factor-alpha in oral lichen planus: a clinicopathologic study in atrophic-erosive and reticular form. J Oral Pathol Med 2009; 38: 559-64.
9. Simark-Mattsson C, Bergenholtz G, Jontell M, et al. Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planus. Arch Oral Biol 1999; 44: 499-507.
10. Khan A, Farah CS, Savage NW, et al. Th1 cytokines in oral lichen planus. J Oral Pathol Med 2003; 32: 77-83.
11. Tao XA, Li CY, Rhodus NL, Xia J, Yang XP, Cheng B. Simultaneous detection of IFN-gamma and IL-4 in lesional tissues and whole unstimulated saliva from patients with oral lichen planus. J Oral Pathol Med 2008; 37: 83-7.
12. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008; 14: 4280-8.
13. Preshaw PM, Taylor JJ. How has research into cytokine interactions and their role in driving immune responses impacted our understanding of periodontitis? J Clin Periodontol 2011; 38(Suppl. 11): 60-84.
14. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28: 477-87.
15. Roescher N, Tak PP, Illei GG. Cytokines in Sjögren's syndrome. Oral Dis 2009; 15: 519-26.
16. Moudgil KD, Choubey D. Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res 2011; 31: 695-703.
17. Ge Y, Xu Y, Sun W, et al. The molecular mechanisms of the effect of Dexamethasone and Cyclosporin A on TLR4/NF-κB signaling pathway activation in oral lichen planus. Gene 2012; 508: 157-64.
18. Piccinni MP, Lombardelli L, Logiodice F, et al. Potential pathogenetic role of Th17, Th0, and Th2 cells in erosive and reticular oral lichen planus. Oral Dis 2014; 20: 212-218.
19. Hu JY, Zhang J, Cui JL, et al. Increasing CCL5/CCR5 on CD4+ T cells in peripheral blood of oral lichen planus. Cytokine 2013; 62: 141-5.
20. Pekiner FN, Demirel GY, Borahan MO, Ozbayrak S. Cytokine profiles in serum of patients with oral lichen planus. Cytokine 2012; 60: 701-6.
21. Kalogerakou F, Albanidou-Farmaki E, Markopoulos AK, Antoniades DZ. Detection of T cells secreting type 1 and type 2 cytokines in the peripheral blood of patients with oral lichen planus. Hippokratia 2008; 12: 230-5.
22. Gotoh A, Hamada Y, Shiobara N, et al. Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection. Clin Exp Immunol 2008; 154: 192-201.
23. Zhang Y, Liu W, Zhang S, et al. Salivary and serum interleukin-18 in patients with oral lichen planus: a study in an ethnic Chinese population. Inflammation 2012; 35: 399-404.
24. Kimkong I, Hirankarn N, Nakkuntod J, Kitkumthorn N. Tumour necrosis factor-alpha gene polymorphisms and susceptibility to oral lichen planus. Oral Dis 2011; 17: 206-9.
25. Xavier GM, de Sá AR, Guimarães AL, da Silva TA, Gomez RS. Investigation of functional gene polymorphisms interleukin-1beta, interleukin-6, interleukin-10 and tumor necrosis factor in individuals with oral lichen planus. J Oral Pathol Med 2007; 36: 476-81.
26. Chauhan I, Beena VT, Srinivas L, Sathyan S, Banerjee M. Association of cytokine gene polymorphisms with oral lichen planus in Malayalam-speaking ethnicity from South India (Kerala). J Interferon Cytokine Res 2013; 33: 420-7.
27. Carrozzo M, Dametto E, Fasano ME, et al. Cytokine gene polymorphisms in hepatitis C virus-related oral lichen planus. Exp Dermatol 2007; 16: 730-6.
28. Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics 2010; 5: 30-55.
29. Dinarello CA. IL-1: discoveries, controversies and future directions. Eur J Immunol 2010; 40: 599-606.
30. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6: 232-41.
31. Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol 2010; 10: 89-102.
32. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012; 11: 633-52.
33. Takeuchi Y, Tohnai I, Kaneda T, Nagura H. Immunohistochemical analysis of cells in mucosal lesions of oral lichen planus. J Oral Pathol 1988; 17: 367-73.
34. Yamamoto T, Osaki T, Yoneda K, Ueta E. Cytokine production by keratinocytes and mononuclear infiltrates in oral lichen planus. J Oral Pathol Med 1994; 23: 309-15.
35. Rhodus NL, Cheng B, Myers S, Bowles W, Ho V, Ondrey F. A comparison of the pro-inflammatory, NF-kappaB-dependent cytokines: TNF-alpha, IL-1-alpha, IL-6, and IL-8 in different oral fluids from oral lichen planus patients. Clin Immunol 2005; 114: 278-83.
36. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 2006; 12: 112-6.
37. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 2005; 44: 77-82.
38. Femiano F, Scully C. Functions of the cytokines in relation oral lichen planus-hepatitis C. Med Oral Patol Oral Cir Bucal 2005; 10(Suppl. 1): E40-4.
39. Carrozzo M, Uboldi de Capei M, Dametto E, et al. Tumor necrosis factor-alpha and interferon-gamma polymorphisms contribute to susceptibility to oral lichen planus. J Invest Dermatol 2004; 122: 87-94.
40. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33: 153-65.
41. Malek TR. The biology of interleukin-2. Annu Rev Immunol 2008; 26: 453-79.
42. Liao W, Lin JX, Leonard WJ. IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation. Curr Opin Immunol 2011; 23: 598-604.
43. Banchereau J, Pascual V, O'Garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines. Nat Immunol 2012; 13: 925-31.
44. Hirota J, Osaki T, Tatemoto Y. Immunohistochemical staining of infiltrates in oral lichen planus. Pathol Res Pract 1990; 186: 625-32.
45. Mattsson T, Sundqvist KG, Heimdahl A, Dahllöf G, Ljungman P, Ringdén O. A comparative immunological analysis of the oral mucosa in chronic graft-versus-host disease and oral lichen planus. Arch Oral Biol 1992; 37: 539-47.
46. Simark-Mattsson C, Bergenholtz G, Jontell M, Tarkowski A, Dahlgren UI. T cell receptor V-gene usage in oral lichen planus; increased frequency of T cell receptors expressing V alpha 2 and V beta 3. Clin Exp Immunol 1994; 98: 503-7.
47. Hasséus B, Jontell M, Brune M, Johansson P, Dahlgren UI. Langerhans cells and T cells in oral graft versus host disease and oral lichen planus. Scand J Immunol 2001; 54: 516-24.
48. Sugerman PB, Savage NW, Seymour GJ. Clonal expansion of lymphocytes from oral lichen planus lesions. J Oral Pathol Med 1993; 22: 126-31.
49. Sugerman PB, Savage NW, Seymour GJ. Phenotype and suppressor activity of T-lymphocyte clones extracted from lesions of oral lichen planus. Br J Dermatol 1994; 131: 319-24.
50. Mozzanica N, Cattaneo A, Legori A, Pigatto P, Finzi AF. Immunohistologic evaluation of the effect of cyclosporine treatment on the lichen planus immune infiltrate. J Am Acad Dermatol 1991; 24: 550-4.
51. Du GH, Qin XP, Li Q, Zhou YM, Shen XM, Tang GY. The high expression level of programmed death-1 ligand 2 in oral lichen planus and the possible costimulatory effect on human T cells. J Oral Pathol Med 2011; 40: 525-32.
52. Zhou G, Zhang J, Ren XW, Hu JY, Du GF, Xu XY. Increased B7-H1 expression on peripheral blood T cells in oral lichen planus correlated with disease severity. J Clin Immunol 2012; 32: 794-801.
53. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol 2010; 10: 225-35.
54. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012; 106: 9-14.
55. Zhu J, Paul WE. Heterogeneity and plasticity of T helper cells. Cell Res 2010; 20: 4-12.
56. Johnson DJ, Pao LI, Dhanji S, Murakami K, Ohashi PS, Neel BG. Shp1 regulates T cell homeostasis by limiting IL-4 signals. J Exp Med 2013; 210: 1419-31.
57. Zhu LY, Pan PP, Fang W, Shao JZ, Xiang LX. Essential role of IL-4 and IL-4Rα interaction in adaptive immunity of zebrafish: insight into the origin of Th2-like regulatory mechanism in ancient vertebrates. J Immunol 2012; 188: 5571-84.
58. Cooney LA, Towery K, Endres J, Fox DA. Sensitivity and resistance to regulation by IL-4 during Th17 maturation. J Immunol 2011; 187: 4440-50.
59. Liu W, Dan H, Wang Z, et al. IFN-gamma and IL-4 in saliva of patients with oral lichen planus: a study in an ethnic Chinese population. Inflammation 2009; 32: 176-81.
60. Ding M, Zeng J, Sroussi H, et al. Interactions between Golli-MBP and Th1/Th2 cytokines in patients with oral lichen planus. Oral Dis 2014; 20: 205-211.
61. Bai J, Lin M, Zeng X, et al. Association of polymorphisms in the human IFN-gamma and IL-4 gene with oral lichen planus: a study in an ethnic Chinese cohort. J Interferon Cytokine Res 2008; 28: 351-8.
62. Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2011; 87: 463-85.
63. Kouro T, Takatsu K. IL-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009; 21: 1303-9.
64. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 2003; 149: 1-38.
65. Dienz O, Rincon M. The effects of IL-6 on CD4 T cell responses. Clin Immunol 2009; 130: 27-33.
66. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011; 1813: 878-88.
67. Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010; 22: 347-52.
68. Gu GM, Martin MD, Darveau RP, Truelove E, Epstein J. Oral and serum IL-6 levels in oral lichen planus patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 673-8.
69. Kho HS, Chang JY, Kim YY, Kim Y. MUC1 and toll-like receptor-2 expression in burning mouth syndrome and oral lichen planus. Arch Oral Biol 2013; 58: 837-42.
70. Zhang Y, Lin M, Zhang S, et al. NF-kappaB-dependent cytokines in saliva and serum from patients with oral lichen planus: a study in an ethnic Chinese population. Cytokine 2008; 41: 144-9.
71. Fayyazi A, Schweyer S, Soruri A, et al. T lymphocytes and altered keratinocytes express interferon-gamma and interleukin 6 in lichen planus. Arch Dermatol Res 1999; 291: 485-90.
72. Karagouni EE, Dotsika EN, Sklavounou A. Alteration in peripheral blood mononuclear cell function and serum cytokines in oral lichen planus. J Oral Pathol Med 1994; 23: 28-35.
73. Sun A, Chia JS, Chang YF, Chiang CP. Serum interleukin-6 level is a useful marker in evaluating therapeutic effects of levamisole and Chinese medicinal herbs on patients with oral lichen planus. J Oral Pathol Med 2002; 31: 196-203.
74. Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 1988; 167: 1883-93.
75. Mukaida N. Pathophysiological roles of interleukin-8/CXCL8 in pulmonary diseases. Am J Physiol Lung Cell Mol Physiol 2003; 284: L566-77.
76. Trompezinski S, Denis A, Schmitt D, Viac J. Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNFalpha. Arch Dermatol Res 2003; 295: 112-6.
77. Simone RE, Russo M, Catalano A, et al. Lycopene inhibits NF-kB-mediated IL-8 expression and changes redox and PPARγ signalling in cigarette smoke-stimulated macrophages. PLoS ONE 2011; 6: e19652.
78. Mukaida N. Interleukin-8: an expanding universe beyond neutrophil chemotaxis and activation. Int J Hematol 2000; 72: 391-8.
79. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
80. Little MC, Griffiths CE, Watson RE, Pemberton MN, Thornhill MH. Oral mucosal keratinocytes express RANTES and ICAM-1, but not interleukin-8, in oral lichen planus and oral lichenoid reactions induced by amalgam fillings. Clin Exp Dermatol 2003; 28: 64-9.
81. Sun A, Wang JT, Chia JS, Chiang CP. Serum interleukin-8 level is a more sensitive marker than serum interleukin-6 level in monitoring the disease activity of oral lichen planus. Br J Dermatol 2005; 152: 1187-92.
82. Dan H, Liu W, Zhou Y, Wang J, Chen Q, Zeng X. Association of interleukin-8 gene polymorphisms and haplotypes with oral lichen planus in a Chinese population. Inflammation 2010; 33: 76-81.
83. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG. Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 2011; 29: 71-109.
84. Sabat R, Grütz G, Warszawska K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev 2010; 21: 331-44.
85. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol 2010; 10: 170-81.
86. Dan H, Liu W, Wang J, et al. Elevated IL-10 concentrations in serum and saliva from patients with oral lichen planus. Quintessence Int 2011; 42: 157-63.
87. Ohno S, Tateishi Y, Tatemoto Y, Morishita K, Sasabe E, Yamamoto T. Enhanced expression of Toll-like receptor 2 in lesional tissues and peripheral blood monocytes of patients with oral lichen planus. J Dermatol 2011; 38: 335-44.
88. Bai J, Jiang L, Lin M, Zeng X, Wang Z, Chen Q. Association of polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes with oral lichen planus: a study in a chinese cohort with Han ethnicity. J Interferon Cytokine Res 2009; 29: 381-8.
89. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85.
90. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8: 40-52.
91. Janardhanam SB, Prakasam S, Swaminathan VT, Kodumudi KN, Zunt SL, Srinivasan M. Differential expression of TLR-2 and TLR-4 in the epithelial cells in oral lichen planus. Arch Oral Biol 2012; 57: 495-502.
92. Gaffen SL. An overview of IL-17 function and signaling. Cytokine 2008; 43: 402-7.
93. Miossec P, Kolls JK. Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 2012; 11: 763-76.
94. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129: 311-21.
95. Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation, autoimmunity, and therapy. J Periodontol 2007; 78: 1083-93.
96. Yu JJ, Gaffen SL. Interleukin-17: a novel inflammatory cytokine that bridges innate and adaptive immunity. Front Biosci 2008; 13: 170-7.
97. Tao XA, Li CY, Xia J, et al. Differential gene expression profiles of whole lesions from patients with oral lichen planus. J Oral Pathol Med 2009; 38: 427-33.
98. Xie S, Ding L, Xiong Z, Zhu S. Implications of Th1 and Th17 cells in pathogenesis of oral lichen planus. J Huazhong Univ Sci Technolog Med Sci 2012; 32: 451-7.
99. Wang H, Luo Z, Lei L, et al. Interaction between oral lichen planus and chronic periodontitis with Th17-associated cytokines in serum. Inflammation 2013; 36: 696-704.
100. Smith DE. The biological paths of IL-1 family members IL-18 and IL-33. J Leukoc Biol 2011; 89: 383-92.
101. Boraschi D, Dinarello CA. IL-18 in autoimmunity: review. Eur Cytokine Netw 2006; 17: 224-52.
102. Orozco A, Gemmell E, Bickel M, Seymour GJ. Interleukin 18 and periodontal disease. J Dent Res 2007; 86: 586-93.
103. Bai J, Zhang Y, Lin M, et al. Interleukin-18 gene polymorphisms and haplotypes in patients with oral lichen planus: a study in an ethnic Chinese cohort. Tissue Antigens 2007; 70: 390-7.
104. Akhurst RJ, Hata A. Targeting the TGFβ signalling pathway in disease. Nat Rev Drug Discov 2012; 11: 790-811.
105. Prime SS, Pring M, Davies M, Paterson IC. TGF-beta signal transduction in oro-facial health and non-malignant disease (part I). Crit Rev Oral Biol Med 2004; 15: 324-36.
106. Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S. TGF-β - an excellent servant but a bad master. J Transl Med 2012; 10: 183.
107. Karatsaidis A, Schreurs O, Axéll T, Helgeland K, Schenck K. Inhibition of the transforming growth factor-beta/Smad signaling pathway in the epithelium of oral lichen. J Invest Dermatol 2003; 121: 1283-90.
108. Zhang J, Zhou G. Green tea consumption: an alternative approach to managing oral lichen planus. Inflamm Res 2012; 61: 535-9.
109. Chen Y, Zhang W, Geng N, Tian K, Jack Windsor L. MMPs, TIMP-2, and TGF-beta1 in the cancerization of oral lichen planus. Head Neck 2008; 30: 1237-45.
110. Vered M, Fürth E, Shalev Y, Dayan D. Inflammatory cells of immunosuppressive phenotypes in oral lichen planus have a proinflammatory pattern of expression and are associated with clinical parameters. Clin Oral Investig 2013; 17: 1365-73.
111. Zhou ZT, Wei BJ, Shi P. Osteopontin expression in oral lichen planus. J Oral Pathol Med 2008; 37: 94-8.
112. Taghavi Zenouz A, Pouralibaba F, Babaloo Z, Mehdipour M, Jamali Z. Evaluation of serum TNF-α and TGF-β in patients with oral lichen planus. J Dent Res Dent Clin Dent Prospects 2012; 6: 143-7.
113. Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004; 75: 163-89.
114. Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 2009; 31: 539-50.
115. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH. Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 2003; 21: 713-58.
116. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T-bet with GATA-3. Science 2005; 307: 430-3.
117. Kelchtermans H, Schurgers E, Geboes L, et al. Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-gamma and counteraction by interferon-gamma. Arthritis Res Ther 2009; 11: R122.
118. Kelchtermans H, Billiau A, Matthys P. How interferon-gamma keeps autoimmune diseases in check. Trends Immunol 2008; 29: 479-86.
119. Simark Mattsson C, Jontell M, Bergenholtz G, Heyden M, Dahlgren UI. Distribution of interferon-gamma mRNA-positive cells in oral lichen planus lesions. J Oral Pathol Med 1998; 27: 483-8.
120. Youngnak-Piboonratanakit P, Dhanuthai K, Thongprasom K, et al. Expression of IFN-gamma before and after treatment of oral lichen planus with 0.1% fluocinolone acetonide in orabase. J Oral Pathol Med 2009; 38: 689-94.
121. Ghallab NA, el-Wakeel N, Shaker OG. Levels of salivary IFN-gamma, TNF-alfa, and TNF receptor-2 as prognostic markers in (erosive) oral lichen planus. Mediators Inflamm 2010; 2010: 847632.
122. Simark-Mattsson C, Eklund C. Reduced immune responses to purified protein derivative and Candida albicans in oral lichen planus. J Oral Pathol Med 2013; 42: 691-7.
123. Yamamoto T, Yoneda K, Ueta E, Osaki T. Cellular immunosuppression in oral lichen planus. J Oral Pathol Med 1990; 19: 464-70.
124. Bradley JR. TNF-mediated inflammatory disease. J Pathol 2008; 214: 149-60.
125. Silva LC, Ortigosa LC, Benard G. Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. Immunotherapy 2010; 2: 817-33.
126. Parameswaran N, Patial S. Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr 2010; 20: 87-103.
127. Um HD, Cho YH, Kim DK, et al. TNF-alpha suppresses dendritic cell death and the production of reactive oxygen intermediates induced by plasma withdrawal. Exp Dermatol 2004; 13: 282-8.
128. Postal M, Appenzeller S. The role of Tumor Necrosis Factor-alpha (TNF-α) in the pathogenesis of systemic lupus erythematosus. Cytokine 2011; 56: 537-43.
129. Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK III. Biology of tumor necrosis factor-alpha- implications for psoriasis. Exp Dermatol 2004; 13: 193-222.
130. Younes F, Quartey EL, Kiguwa S, Partridge M. Expression of TNF and the 55-kDa TNF receptor in epidermis, oral mucosa, lichen planus and squamous cell carcinoma. Oral Dis 1996; 2: 25-31.
131. Sklavounou A, Chrysomali E, Scorilas A, Karameris A. TNF-alpha expression and apoptosis-regulating proteins in oral lichen planus: a comparative immunohistochemical evaluation. J Oral Pathol Med 2000; 29: 370-5.
132. Karatsaidis A, Hayashi K, Schreurs O, Helgeland K, Schenck K. Survival signalling in keratinocytes of erythematous oral lichen planus. J Oral Pathol Med 2007; 36: 215-22.
133. Thongprasom K, Dhanuthai K, Sarideechaigul W, Chaiyarit P, Chaimusig M. Expression of TNF-alpha in oral lichen planus treated with fluocinolone acetonide 0.1%. J Oral Pathol Med 2006; 35: 161-6.
134. Zhao ZZ, Sugerman PB, Zhou XJ, Walsh LJ, Savage NW. Mast cell degranulation and the role of T cell RANTES in oral lichen planus. Oral Dis 2001; 7: 246-51.
135. Zhou XJ, Sugerman PB, Savage NW, Walsh LJ. Matrix metalloproteinases and their inhibitors in oral lichen planus. J Cutan Pathol 2001; 28: 72-82.
136. Sugermann PB, Savage NW, Seymour GJ, Walsh LJ. Is there a role for tumor necrosis factor-alpha (TNF-alpha) in oral lichen planus? J Oral Pathol Med 1996; 25: 219-24.
137. Pezelj-Ribaric S, Prso IB, Abram M, Glazar I, Brumini G, Simunovic-Soskic M. Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm 2004; 13: 131-3.
138. Yamamoto T, Yoneda K, Ueta E, Hirota J, Osaki T. Serum cytokine levels in patients with oral mucous membrane disorders. J Oral Pathol Med 1991; 20: 275-9.
139. Yamamoto T, Yoneda K, Ueta E, Osaki T. Serum cytokines, interleukin-2 receptor, and soluble intercellular adhesion molecule-1 in oral disorders. Oral Surg Oral Med Oral Pathol 1994; 78: 727-35.
140. Sklavounou-Andrikopoulou A, Chrysomali E, Iakovou M, Garinis GA, Karameris A. Elevated serum levels of the apoptosis related molecules TNF-alpha, Fas/Apo-1 and Bcl-2 in oral lichen planus. J Oral Pathol Med 2004; 33: 386-90.
141. Sun A, Chia JS, Wang JT, Chiang CP. Levamisole can reduce the high serum tumour necrosis factor-alpha level to a normal level in patients with erosive oral lichen planus. Clin Exp Dermatol 2007; 32: 308-10.
142. Qidwai T, Khan F. Tumour necrosis factor gene polymorphism and disease prevalence. Scand J Immunol 2011; 74: 522-47.
143. Jin X, Wang J, Zhu L, et al. Association between -308 G/A polymorphism in TNF-α gene and lichen planus: a meta-analysis. J Dermatol Sci 2012; 68: 127-34.
144. O'Neill ID. Off-label use of biologicals in the management of inflammatory oral mucosal disease. J Oral Pathol Med 2008; 37: 575-81.
145. Worsnop F, Wee J, Natkunarajah J, Moosa Y, Marsden R. Reaction to biological drugs: infliximab for the treatment of toxic epidermal necrolysis subsequently triggering erosive lichen planus. Clin Exp Dermatol 2012; 37: 879-81.
146. Zhang J, Zhou G, Du GF, Xu XY, Zhou HM. Biologics, an alternative therapeutic approach for oral lichen planus. J Oral Pathol Med 2011; 40: 521-4.
147. O'Neill ID, Scully C. Biologics in oral medicine: ulcerative disorders. Oral Dis 2013; 19: 37-45.